✨ Free AI Report
Neuren Pharmaceuticals Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Neuren Pharmaceuticals Limited
Company Research

Neuren Pharmaceuticals Limited: Business Overview, Financials & Competitive Analysis

Neuren Pharmaceuticals Limited scores 6/10 on the AskCyborg Cyborg Score (Solid). Early-stage biotech with validated first-in-class therapy commercialization and high-value pipeline, but significant single-asset dependency limits upside certainty. Strong financial position and partnerships reduce capital raising needs, while international expansion and R&D investments present significant growth opportunities. However, heavy reliance on DAYBUE creates revenue concentration risk, and growing competition with.

What is Neuren Pharmaceuticals Limited's industry? Neuren Pharmaceuticals Limited (neurenpharma.com) operates in Biopharmaceuticals - Orphan and Rare Diseases. AskCyborg classifies Neuren Pharmaceuticals Limited under Biopharmaceuticals - Orphan and Rare Diseases in its company registry.

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for the treatment of neurological disorders. The company focuses on rare neurodevelopmental diseases with limited or no approved treatment...

6/ 10Solid

Cyborg Score thesis

Early-stage biotech with validated first-in-class therapy commercialization and high-value pipeline, but significant single-asset...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Orphan and Rare Diseases
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Neuren Pharmaceuticals Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Neuren Pharmaceuticals Limited

AskCyborg analysts argue the bull and bear cases for Neuren Pharmaceuticals Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Neuren Pharmaceuticals Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Neuren Pharmaceuticals Limited Overview

Pro stress-test →

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for the treatment of neurological disorders. The company focuses on rare neurodevelopmental diseases with limited or no approved treatment options, leveraging proprietary technologies and partnerships to bring first-in-class therapies to market.

Strategic Profile

Pro stress-test →

The FDA approved DAYBUE (trofinetide) for Rett syndrome treatment in March 2023, with Acadia Pharmaceuticals holding worldwide exclusive license rights. The company's second product NNZ-2591 is in Phase 2 trials for multiple rare syndromes affecting approximately five times the patient population of Rett syndrome.

Competitive Landscape

Pro stress-test →

Neuren operates in the rare neurodevelopmental disorder space with limited direct competitors due to orphan designations. No approved drugs exist for Phelan-McDermid, Angelman, or Pitt Hopkins syndromes outside growth hormone for Prader-Willi. Competitive threats come from larger biotech/pharma companies developing alternative mechanisms.

Industry Context

Neuren Pharmaceuticals Limited operates in Biopharmaceuticals - Orphan and Rare Diseases.

Key facts

Founded: 2001 · Headquarters: Hawthorn East, Australia · Revenue: A$84.84M (FY2025) · Market cap: A$1.64B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Neuren Pharmaceuticals Limited.

  • Full-year 2025 revenue was A$84.84 million with net income of A$30.44 million, reflecting strong DAYBUE performance.
  • DAYBUE is the first and only drug approved for treating Rett syndrome, providing first-mover advantage in this orphan indication.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Trading pause on ASX pending market-sensitive announcement regarding pipeline progress
  • February 2026Full-year 2025 results reported with A$84.84 million revenue; announced on-market share buy-back program
  • +1 moreTrack every material event for Neuren Pharmaceuticals Limited as it happens. Explore monitoring →
Get alerted when Neuren Pharmaceuticals Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Genetic and neurological disorder therapeuticsPartner company holding exclusive license for trofinetide and NNZ-2591 commercialization in key indications→Rare pediatric neurological therapeuticsEmerging competitors in orphan indication space for neurodevelopmental disorders→

Compare Neuren Pharmaceuticals Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neuren Pharmaceuticals Limited operates in Biopharmaceuticals - Orphan and Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Orphan and Rare Diseases research →
NEW · MCP server

Ask your AI assistant about Neuren Pharmaceuticals Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neuren Pharmaceuticals Limited and its top competitor on Cyborg Score”
“What did Neuren Pharmaceuticals Limited do this quarter?”
“Is Neuren Pharmaceuticals Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Neuren Pharmaceuticals Limited do?+
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for the treatment of neurological disorders. The company focuses on rare neurodevelopmental diseases with limited or no approved treatment...
What is Neuren Pharmaceuticals Limited's Cyborg Score?+
Neuren Pharmaceuticals Limited has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neuren Pharmaceuticals Limited's main competitors?+
Named competitors include Genetic and neurological disorder therapeutics, Rare pediatric neurological therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Neuren Pharmaceuticals Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neuren Pharmaceuticals Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neuren Pharmaceuticals Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.